Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pathways

Müller‐Berghaus, Gert

doi:10.1055/s-2007-1002690

Cited by 133 publications

(77 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disseminated intravascular coagulation (DIC) [1][2][3] is a frequent complication of inflammatory disease and trauma. Patients with this complication often have severe organ failure and are usually admitted to the intensive care unit (ICU).…”

Section: Introductionmentioning

confidence: 99%

Hemostatic markers and the sepsis‐related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit

et al. 2004

View full text Add to dashboard Cite

We investigated the correlation between disseminated intravascular coagulation (DIC) score and hemostatic parameters and sepsis-related organ failure assessment (SOFA) score with clinical outcome of patients with DIC in an intensive care unit (ICU). The SOFA score was markedly elevated in patients with DIC relative to patients without DIC and significantly higher in non-survivors than in survivors. Abnormalities in almost all hemostatic parameters were significant in patients with DIC, but there was no significant difference in almost all hemostatic parameters between survivors and non-survivors. However, plasma antithrombin (AT) levels were significantly lower in non-survivors than in survivors. Soluble fibrin (SF) and tissue type plasminogen activator (tPA)-plasminogen activator inhibitor-I (PAI-I) complex correlated significantly with the SOFA score, whereas AT levels correlated significantly and negatively with the SOFA score. We conclude that the SOFA score is useful for predicting outcome in DIC patients in the ICU, and that hemostatic parameters, especially plasma AT levels, are also useful markers for organ failure and clinical outcome. Am.

show abstract

Section: Introductionmentioning

confidence: 99%

Hemostatic markers and the sepsis‐related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit

et al. 2004

View full text Add to dashboard Cite

show abstract

“…sepsis* tissue factor -inflammation Disseminated intravascular coagulation (DIC)' is a disorder that occurs in response to invading microorganisms and tissue injury characterized by widespread deposition of fibrin in blood vessels. One of the initiating causes of DIC appears to be the inappropriate exposure of the blood to tissue factor ( 1). During this process, there is consumption of fibrinogen, a reduction in platelet count, and increases in prothrombin and activated partial thromboplastin times.…”

Section: Introductionmentioning

confidence: 99%

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Creasey¹,

Chang²,

Feigen³

et al. 1993

J. Clin. Invest.

539

318

View full text Add to dashboard Cite

“…TFPI consists of three Kunitz type inhibitory domains [7]; the second Kunitz domain is the FXa inhibitor, while the first domain is responsible for FVIIa/tissue factor (TF) inhibition [8]. Disseminated intravascular coagulation (DIC) [9,10], a condition associated with severe bleeding tendency and organ failure and sometimes exhibiting a very rapid and severe clinical course, appears to be related to vascular endothelial cell injury. Recently, plasma levels of other agents involved in the coagulation cascade, i.e., thrombomodulin (TM), tissue type plasminogen activator (t-PA), plasminogen activator inhibitor-I (PAI-I), and von Willebrand Factor (vWF), all of which are released from vascular endothelial cells, have been reported [11,12].…”

Section: Introductionmentioning

confidence: 99%

Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation

et al. 1997

View full text Add to dashboard Cite

We measured the plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with disseminated intravascular coagulation (DIC) to examine the relationship between TFPI and vascular endothelial cell injury. Plasma TF (273 ± 90 pg/ml) and TFPI (252 ± 125 ng/ml) levels were significantly increased in patients with DIC compared with non-DIC patients. Plasma TF antigen level was significantly increased in pre-DIC patients (285 ± 85 pg/ml), while the plasma TFPI level (152 ± 54 ng/ml) was not markedly increased in such a state. The plasma TF/TFPI ratio was high in the pre-DIC patients (2.10 ± 0.90), and low in the DIC patients (1.40 ± 0.87) and healthy volunteers (0.84 ± 0.26). There was no significant difference between the DIC patients with a good outcome and those with a poor outcome in terms of plasma TF levels, although the plasma TFPI level in the DIC patients with a good outcome (289 ± 133 ng/ml) was significantly higher than those with a poor outcome (187 ± 75 ng/ml). During the clinical course of DIC, plasma TF antigen was increased first, and an increase of the plasma TFPI level followed the increase in plasma TF level. These findings suggest that plasma TFPI is released from vascular endothelial cells and it may reflect vascular endothelial cell injury. It is conceivable that TF and TFPI may play an important role in the onset of DIC. Am.

show abstract

Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pathways

Cited by 133 publications

References 208 publications

Hemostatic markers and the sepsis‐related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit

Hemostatic markers and the sepsis‐related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation

Contact Info

Product

Resources

About